Analyst Price Target is $12.00
▲ +380.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PolyPid in the last 3 months. The average price target is $12.00, with a high forecast of $14.00 and a low forecast of $10.00. The average price target represents a 380.00% upside from the last price of $2.50.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in PolyPid. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Read More